.png)
.png)
Latest news from BIA
2021 on track to be another record-breaking year for UK biotech investment as investors see returns from the maturing sector
UK biotech companies are on track for a record-breaking year of fundraising according to the latest data released by the UK BioIndustry Association (BIA) and Clarivate. More than £830m in fresh capital was raised in the three months to the end of February, almost topping the £894m raised in the first six months of 2020, which itself was a record-breaking year.
BIA welcomes £1bn investment deal and launch of Life Sciences Investment Programme
Steve Bates OBE, Chief Executive of the BioIndustry Association said: “Congratulations to the Government’s new Office for Investment for securing the £1 billion UAE-UK Sovereign Investment Partnership, which I am delighted to see focused on the opportunities in UK life sciences.
BIA urges the Government to take a science-based approach to regulation of gene editing and GMOs
The BioIndustry Association (BIA) has urged the Government to adopt a science-based and innovation-friendly regulatory framework for gene editing and genetically modified organisms (GMOs).
BIA welcomes updated guidance from the MHRA on approved countries for batch testing
The BioIndustry Association (BIA) has welcomed updated guidance from the MHRA published today which makes changes to the list of approved countries for batch testing and the importation of medicines.
HotHouse BioEngineering and Leaf Expression Systems Sign Plant-Based Expression License Agreement
NORWICH, UK – 13 April 2021: HotHouse BioEngineering (HHBE), which was founded on a body of work from the laboratory of Professor Anne Osbourn FRS OBE of the John Innes Centre, and Leaf Expression Systems (Leaf), a contract development and manufacturing organisation specialising in plant-based expression and production of proteins, today announced a non-exclusive agreement granting HHBE use of Leaf’s expression technology, Hypertrans® for research and development.
R&D Tax Credits – The three most common areas life sciences companies underclaim
We all know how important R&D tax credits are for the Life Sciences, Pharmaceuticals, and Biotech sectors. Most companies in these industries have been claiming since day one, and yet we often encounter companies who are significantly underclaiming. The average benefit for companies in these industries is just over £110k, but Ayming’s average claim for companies in these industries is currently more than £700k, so why is there such a discrepancy?
Medannex unveils the multiple anti-cancer effects of MDX-124 at AACR Annual Meeting 2021
Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the American Association for Cancer Research (AACR), highlighting the multi-faceted anti-cancer activity of MDX-124 - the company’s proprietary therapeutic antibody.
Cancer Research UK launches new ‘cancer tech accelerator’ programme
Cancer Research UK and Capital Enterprise, together with Roche UK, have launched the Cancer Tech Accelerator programme to support innovative technologies that can advance the early detection, diagnosis, monitoring or treatment of cancer.
Guest Blog|Incentivising innovation in life sciences requires a fresh debate
New incentives should be explored to encourage innovation in life sciences, especially in areas where the traditional model of incentives might not be working or sufficiently encouraging the development of medicines that society needs.
CEO Update | Monday 12 April
It was fantastic to see the launch of the Medicines & Diagnostics Manufacturing Transformation Fund which aims to boost economic opportunities, innovation and health resilience by supporting medicines and diagnostics manufacturing investments in the UK.
Guest Blog|Could our immune system be why COVID-19 is so deadly?
Respiratory viruses such as SARS-CoV-2 often catalyse an overactive immune response that leads to a life-threatening cycle, known as a cytokine storm. Analysing cytokine responses from patients has unearthed glaringly important differences in how SARS-CoV-2 affects cytokines compared to other common respiratory viruses.
National Security and Investment Bill Webinar Q&A
Last month, the BIA hosted a webinar to delve deeper into the impact of the National Security and Investment Bill on the UK life sciences sector and hear from members about their concerns. In this blogpost, we provide answers to the remainder of questions which came up in the session.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector | BIA update: October 2019 - January 2020
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.
Global and growing - UK biotech financing in 2019
New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.
UK life sciences: Catalysing investment and growth
This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.
BIA biotech manifesto 2019
The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.
